Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a ...

Summary. Despite solid earnings beats, Blueprint Medicines is trading down ~16% since my last article. AYVAKIT/AYVAKYT revenues have doubled for four consecutive years, with 2024 guidance pegging ...

After reporting second-quarter financial results and updating investors on the progress it's making in developing cancer therapies targeting specific genetic mutations, Blueprint Medicines (NASDAQ ...

Blueprint Medicines (NASDAQ:BPMC) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

Blueprint Medicines' stock was stagnant in 2024 and is up just 2% since my rating upgrade to "strong buy" in February.Back then, my focus was on the company's lead drug, Ayvakit, to treat advanced ...

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, ...

Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter: These 10 analysts have an average price target of $69.0 versus the current price of ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...